

PATIENT CONSENT

Dear Roche Patient Program Enrollee (“You”):

Hoffmann-La Roche Limited (“Roche”) has retained Innomar Strategies Inc. (“Innomar”) to administer certain Roche-sponsored patient support programs, including the Roche Patient Assistance Program (“RPAP”), **Jointeffort**®, Easy START®, ERIVEDGE® (vismodegib) Pregnancy Prevention Program (“EPPP”), and INSPIRATION™ (collectively, the “Programs”), the purpose of which are to assist Canadian patients to obtain access to medical treatment. You have enrolled, or are applying to enroll, in one or more of these Programs. While Innomar and Roche endeavour to assist all applicants to a Program, neither Innomar nor Roche guarantee successful or continued access to treatment or other Program services, and Roche and Innomar reserve the right to revise or cancel any aspect of a Program at any time and without notice.

Collection and Use of Personal Information

Innomar, Roche and their employees, representatives and consultants may collect and share personal information about you (such as your name, address, phone number, financial information, personal health information such as information about your medical condition and/or health insurance) either directly from you, from your authorized representative, from your healthcare provider or from your health benefit insurer, and may use, store and disclose in confidence this information for the purpose of administering, managing and delivering the Program, including determining Program eligibility, providing and coordinating applicable Program services (such as reimbursement assistance, insurance coverage verification, and coordinating/providing infusion and injection services), making you aware of other patient support programs that may be of interest to you, and performing customer satisfaction surveys. Your personal information may also be disclosed to representatives of Roche for monitoring and auditing purposes. Your personal information may be held and used in, and transferred to, any province or country worldwide, including those whose privacy laws may be different or less stringent than the laws of your home province, for the purposes identified in this document.

Your personal information may also be held, used and disclosed as may be required or advisable to comply with applicable laws, including for the purpose of reporting of any adverse drug health events to Health Canada. In this regard, Innomar and/or Roche may collect and provide to Roche’s drug safety department details of any adverse health event you may experience while using a Roche product. Typically, these details will not disclose information which may readily identify you, but may include identifiers (your initials, date of birth or age, height, weight) and information about the adverse event you may have experienced. You may also be asked to allow Innomar and/or Roche drug safety to contact you or your health care provider(s) in case any further clarification regarding the adverse drug event is needed. Any adverse drug event information provided to the Roche drug safety department will be stored for the period of time required by law and may be shared internationally with the Roche group of companies and regulatory authorities as required by applicable law.

If at any time and for any reason Roche appoints a new company to replace Innomar as the administrator of a Program, your records may be transferred to the new administrator designated by Roche, for the purpose of continuing your participation in the Program, in the same manner as required of Innomar as described above. Innomar may, after this transfer, still retain such records or copies of records for the purpose of compliance with laws and regulations relating to retention of personal and medical records.

Neither Roche nor Innomar will ever sell your name or other personal information, or use or disclose your personal information for purposes other than what it was collected for or as otherwise identified in this document, unless required or permitted by law.

Patient Contact

When enrolled in a Program, you will be contacted by representatives of the Program for the purpose of administering the Program services, including by means of telephone and electronic messaging (e.g., email). You may also be contacted by third party representatives of Roche or Innomar for the purpose of customer satisfaction follow up surveys concerning the Program services you receive, including by means of telephone and electronic messaging (e.g., email), and your contact details may be provided to such third parties for this purpose.

Withdrawing From Program/Correcting Information

Your continued participation and enrollment in the Program indicates your agreement to these terms and conditions and consent to the collection and use of your personal information in accordance with the above. You may at any time obtain a copy of your personal information from Innomar and can correct any errors and/or direct any questions regarding the collection, use, disclosure and storage of your personal information by writing to Innomar at the relevant address or fax number (see enclosed contact details). You may also withdraw yourself from a Program by sending a letter to the Program at the relevant address or fax number (see enclosed contact details). Withdrawing your enrollment and consent will end further uses and disclosures of your personal information (although it is not retroactive), however since Roche and Innomar need to use your personal information to perform Program services, if you withdraw your enrollment and consent your Program services will end.

Roche Patient Program Contact Details

Roche Jointeffort Program
c/o Innomar Strategies Inc.
3470 Superior Court
Oakville, ON L6L 0C4
Tel: 1-888-748-8926
Fax: 1-888-532-1198